Arriving new drugs for the treatment ofhepatitis C, more quick and effective. This was explained by the director general of AIFA, Mario Melazzini, who this morning presented the new criteria for access to second generation anti-hepatitis C medicines, defined by the Italian Medicines Agency in agreement with scientific societies. Soon - AIFA underlines - they will be available in 
trade new products for the treatment of infection, characterized by greater efficacy and shorter duration of therapy, compared to the therapeutic options available today.
It is in fact underway at Aifa la reimbursement negotiation and the pricing of the drug Epclusa* (sofosbuvir/velpatasvir) for the treatment of all genotypes (pan-genotypic action) of the HCV virus and is authorization expected by June 2017 with an accelerated procedure by the European Medicines Agency Ema of another medicinal product (glecaprevir/pibrentasvir) also with pan-genotypic action.
Furthermore, numerous combinations of active ingredients and new combinations are being tested in clinical trials in order to expand the number of therapeutic options, especially for the more difficult to treat subgroups of patients, to reduce the duration of therapy and increase the manageability of the treatment. The duration of treatment is variable: 8, 12, 24 weeks, and in some cases 48 weeks. Currently, there are 6 new drugs available for the treatment of hepatitis C: Sovaldi*, Harvoni*, Viekirax* + Exviera*, Olysio*, Daklinza*, Zepatier*.
Posted on: 21/03/2017 – adnkronos
Related news: Prices of innovative drugs. A lot of indignation, but the expenditure is only one 837th of public spending
